Integer Stock Down 28% as Insider Reports Sale. Here's What to Know

VP Tom Thomas sold 825 shares of Integer (ITGR) on March 13, 2026 for $70,000, representing 15.85% of his direct holdings and leaving him with 4,381 direct shares (post-sale value ≈ $364k). Integer delivered FY2025 revenue of ~$1.85bn (+8% YoY), adjusted operating income +13% and adjusted EPS +21%, but shares are down ~27.7% over the past year and leverage is elevated near 3.0x EBITDA with net debt up $195m to $1.185bn. The sale is described as routine liquidity management given prior small open-market sales and is unlikely to materially affect the stock.

Analysis

Integer operates at the intersection of secular growth in complex implantable devices and the thin-margin world of precision contract manufacturing. That combination creates asymmetric outcomes: modest topline slips or a single large OEM re-source decision can compress FCF materially, while successful product ramps and factory utilization improvements can meaningfully lift adjusted margins and free cash flow.

Higher financial leverage amplifies these operating moves into balance-sheet risk and M&A optionality: management can either prioritize deleveraging (selling assets, slowing buybacks) or pursue tuck-ins that boost scale but push leverage further, changing equity upside/capital structure dynamics over 12–24 months. Also watch OEM behavior — as device complexity rises, some large customers may prefer to internalize critical subsystems, which would shift revenue mix and the stability of Integer’s book in a way that is not visible from headline growth numbers.

Supply-chain and reimbursement second-order effects matter more here than for general industrials: component cost deflation or extended lead-time normalization can convert into outsized margin tailwinds given the firm’s cost base; conversely, regulatory slowdowns or CMS reimbursement pressure on elective procedures would quickly reduce demand for core cardio/vascular ramps. Finally, insider liquidity moves appear logistical; the real market signal will be capital allocation choices (debt repayments, M&A cadence) and next two guidance prints, which will set the 12-month path for deleveraging and valuation multiple re-rating.

Key Decisions for Investors

• Event-driven long: Buy a 12–18 month ITGR call spread (buy 30% OTM / sell 60% OTM) sized to 2–3% portfolio notional. Rationale: captures asymmetric upside if margins and FCF inflect higher while limiting premium decay; take profits if shares double or if net leverage falls meaningfully within 12 months.
• Relative-value pair: Long ITGR equity (or 9–12 month near-the-money calls) and short a large diversified medtech (e.g., MDT) in a 1:1 delta-adjusted ratio for 6–12 months. Rationale: isolates contract-manufacturing margin expansion vs OEM end-market cyclicality; cut the pair if spread widens >10% adverse or after the next two earnings releases.
• Hedge/short volatility: Buy a 3–6 month ITGR put spread ~15%–25% OTM to protect against an earnings/volume miss driven by OEM re-sourcing or reimbursement news. Size to cover core position risk; max loss limited to premium, max gain if share price falls sharply up to strike differential.
• Monitor & trigger alerts: Set alerts for (1) next two guidance updates, (2) net leverage moves >1 turn, and (3) any large OEM contract loss/award. Use these as explicit trade triggers to add to long exposure on confirmed deleveraging or unwind on visible customer concentration loss.